{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,30]],"date-time":"2026-10-30T05:33:07Z","timestamp":1793338387979,"version":"4.5.0"},"reference-count":32,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T00:00:00Z","timestamp":1761955200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T00:00:00Z","timestamp":1761955200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T00:00:00Z","timestamp":1761955200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T00:00:00Z","timestamp":1761955200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T00:00:00Z","timestamp":1761955200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T00:00:00Z","timestamp":1761955200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T00:00:00Z","timestamp":1761955200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["American Heart Journal"],"published-print":{"date-parts":[[2025,11]]},"DOI":"10.1016\/j.ahj.2025.06.010","type":"journal-article","created":{"date-parts":[[2025,6,21]],"date-time":"2025-06-21T10:52:03Z","timestamp":1750503123000},"page":"171-179","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":11,"special_numbering":"C","title":["Global lipoprotein (a) testing trends from 2015 to 2023"],"prefix":"10.1016","volume":"289","author":[{"given":"Muhammad","family":"Hanif","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9361-572X","authenticated-orcid":false,"given":"Laibah Arshad","family":"Khan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anandita","family":"Kulkarni","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Harpreet S.","family":"Bhatia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael J.","family":"Wilkinson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ahmed Mustafa","family":"Rashid","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicholas W.S.","family":"Chew","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Subhash","family":"Banerjee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Javed","family":"Butler","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael D.","family":"Shapiro","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Muhammad Shahzeb","family":"Khan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"11","key":"10.1016\/j.ahj.2025.06.010_bib0001","doi-asserted-by":"crossref","first-page":"1953","DOI":"10.1194\/jlr.R071233","article-title":"Langsted A. Lipoprotein (a) as a cause of cardiovascular disease: insights from epidemiology, genetics, and biology","volume":"57","author":"Nordestgaard","year":"2016","journal-title":"J Lipid Res"},{"issue":"39","key":"10.1016\/j.ahj.2025.06.010_bib0002","doi-asserted-by":"crossref","first-page":"3925","DOI":"10.1093\/eurheartj\/ehac361","article-title":"Lipoprotein(a) in atherosclerotic cardiovascular disease and aortic stenosis: a European Atherosclerosis Society consensus statement","volume":"43","author":"Kronenberg","year":"2022","journal-title":"Eur Heart J"},{"issue":"4","key":"10.1016\/j.ahj.2025.06.010_bib0003","doi-asserted-by":"crossref","first-page":"385","DOI":"10.1177\/1358863X221091320","article-title":"Elevated lipoprotein(a) levels and risk of peripheral artery disease outcomes: a systematic review","volume":"27","author":"Masson","year":"2022","journal-title":"Vasc Med"},{"issue":"1","key":"10.1016\/j.ahj.2025.06.010_bib0004","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1016\/j.jacc.2019.03.524","article-title":"Elevated lipoprotein(a) and risk of ischemic stroke","volume":"74","author":"Langsted","year":"2019","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.ahj.2025.06.010_bib0005","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1016\/j.atherosclerosis.2021.06.004","article-title":"Lipoprotein(a) levels and atherosclerotic plaque characteristics in the carotid artery: the Plaque at RISK (PARISK) study","volume":"329","author":"van Dam-Nolen","year":"2021","journal-title":"Atherosclerosis"},{"issue":"1","key":"10.1016\/j.ahj.2025.06.010_bib0006","doi-asserted-by":"crossref","first-page":"78","DOI":"10.1016\/j.jchf.2015.08.006","article-title":"Elevated lipoprotein(a) levels, LPA risk genotypes, and increased risk of heart failure in the general population","volume":"4","author":"Kamstrup","year":"2016","journal-title":"JACC Heart Fail"},{"issue":"25","key":"10.1016\/j.ahj.2025.06.010_bib0007","doi-asserted-by":"crossref","first-page":"2761","DOI":"10.1016\/j.jacc.2016.10.033","article-title":"Phenotypic characterization of genetically lowered human lipoprotein(a) levels","volume":"68","author":"Emdin","year":"2016","journal-title":"J Am Coll Cardiol"},{"issue":"10459","key":"10.1016\/j.ahj.2025.06.010_bib0008","doi-asserted-by":"crossref","first-page":"1255","DOI":"10.1016\/S0140-6736(24)01308-4","article-title":"Lipoprotein(a) and cardiovascular disease","volume":"404","author":"Nordestgaard","year":"2024","journal-title":"The Lancet"},{"issue":"5","key":"10.1016\/j.ahj.2025.06.010_bib0009","doi-asserted-by":"crossref","first-page":"421","DOI":"10.1016\/j.jacc.2021.04.102","article-title":"Lipoprotein(a) and benefit of PCSK9 inhibition in patients with nominally controlled LDL cholesterol","volume":"78","author":"Schwartz","year":"2021","journal-title":"J Am Coll Cardiol"},{"issue":"5","key":"10.1016\/j.ahj.2025.06.010_bib0010","doi-asserted-by":"crossref","first-page":"e738","DOI":"10.1016\/j.jacl.2024.04.134","article-title":"Long-term lipoprotein apheresis reduces cardiovascular events in high-risk patients with isolated lipoprotein(a) elevation","volume":"18","author":"Schumann","year":"2024","journal-title":"J Clin Lipidol"},{"issue":"21","key":"10.1016\/j.ahj.2025.06.010_bib0011","doi-asserted-by":"crossref","first-page":"2075","DOI":"10.1001\/jama.2023.21835","article-title":"Lepodisiran, an extended-duration short interfering RNA targeting lipoprotein(a)","volume":"330","author":"Nissen","year":"2023","journal-title":"JAMA"},{"issue":"20","key":"10.1016\/j.ahj.2025.06.010_bib0012","doi-asserted-by":"crossref","first-page":"1855","DOI":"10.1056\/NEJMoa2211023","article-title":"Small interfering RNA to reduce lipoprotein(a) in cardiovascular disease","volume":"387","author":"O\u2019Donoghue","year":"2022","journal-title":"N Engl J Med"},{"issue":"1","key":"10.1016\/j.ahj.2025.06.010_bib0013","doi-asserted-by":"crossref","first-page":"96","DOI":"10.1038\/s41591-021-01634-w","article-title":"Preclinical development and phase 1 trial of a novel siRNA targeting lipoprotein(a)","volume":"28","author":"Koren","year":"2022","journal-title":"Nat Med"},{"issue":"3","key":"10.1016\/j.ahj.2025.06.010_bib0014","doi-asserted-by":"crossref","first-page":"244","DOI":"10.1056\/NEJMoa1905239","article-title":"Lipoprotein(a) reduction in persons with cardiovascular disease","volume":"382","author":"Tsimikas","year":"2020","journal-title":"N Engl J Med"},{"issue":"3","key":"10.1016\/j.ahj.2025.06.010_bib0015","doi-asserted-by":"crossref","first-page":"222","DOI":"10.1001\/jama.2024.24017","article-title":"Oral Muvalaplin for lowering of lipoprotein(a)","volume":"333","author":"Nicholls","year":"2025","journal-title":"JAMA"},{"issue":"23","key":"10.1016\/j.ahj.2025.06.010_bib0016","doi-asserted-by":"crossref","first-page":"1992","DOI":"10.1001\/jama.2024.21957","article-title":"Zerlasiran\u2014A small-interfering RNA targeting lipoprotein(a)","volume":"332","author":"Nissen","year":"2024","journal-title":"JAMA"},{"issue":"1","key":"10.1016\/j.ahj.2025.06.010_bib0017","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1007\/s40119-024-00353-w","article-title":"Targeting lipoprotein(a): can RNA therapeutics provide the next step in the prevention of cardiovascular disease?","volume":"13","author":"Thau","year":"2024","journal-title":"Cardiol Ther"},{"issue":"1","key":"10.1016\/j.ahj.2025.06.010_bib0018","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1093\/eurheartj\/ehz455","article-title":"2019 ESC\/EAS Guidelines for the management of dyslipidaemias: lipid modification to reduce cardiovascular risk","volume":"41","author":"Mach","year":"2020","journal-title":"Eur Heart J"},{"issue":"24","key":"10.1016\/j.ahj.2025.06.010_bib0019","first-page":"3234","article-title":"2018 AHA\/ACC\/AACVPR\/AAPA\/ABC\/ACPM\/ADA\/AGS\/APhA\/ASPC\/NLA\/PCNA guideline on the management of blood Cholesterol: a report of the American College of Cardiology\/American Heart Association Task Force on Clinical Practice Guidelines","volume":"73","author":"Grundy","year":"2019","journal-title":"Circulation"},{"key":"10.1016\/j.ahj.2025.06.010_bib0020","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1016\/j.amjcard.2021.05.018","article-title":"Lipoprotein(a) testing patterns in a large health system","volume":"153","author":"Kelsey","year":"2021","journal-title":"Am J Cardiol"},{"issue":"18","key":"10.1016\/j.ahj.2025.06.010_bib0021","doi-asserted-by":"crossref","DOI":"10.1161\/JAHA.123.031255","article-title":"Lipoprotein(a) testing trends in a large academic health system in the United States","volume":"12","author":"Bhatia","year":"2023","journal-title":"J Am Heart Assoc"},{"key":"10.1016\/j.ahj.2025.06.010_bib0022","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1200\/CCI.17.00067","article-title":"Using a federated network of real-world data to optimize clinical trials operations","volume":"2","author":"Topaloglu","year":"2018","journal-title":"JCO Clin Cancer Inform"},{"issue":"2","key":"10.1016\/j.ahj.2025.06.010_bib0023","doi-asserted-by":"crossref","DOI":"10.1093\/jamiaopen\/ooad035","article-title":"A global federated real-world data and analytics platform for research","volume":"6","author":"Palchuk","year":"2023","journal-title":"JAMIA Open"},{"issue":"8","key":"10.1016\/j.ahj.2025.06.010_bib0024","first-page":"1129","article-title":"2021 Canadian cardiovascular society guidelines for the management of dyslipidemia for the prevention of Cardiovascular disease in adults","volume":"37","author":"Pearson","year":"2021","journal-title":"Canad J Cardiol"},{"issue":"3","key":"10.1016\/j.ahj.2025.06.010_bib0025","doi-asserted-by":"crossref","first-page":"e308","DOI":"10.1016\/j.jacl.2024.03.001","article-title":"A focused update to the 2019 NLA scientific statement on use of lipoprotein(a) in clinical practice","volume":"18","author":"Koschinsky","year":"2024","journal-title":"J Clin Lipidol"},{"issue":"10","key":"10.1016\/j.ahj.2025.06.010_bib0026","doi-asserted-by":"crossref","first-page":"1196","DOI":"10.4158\/CS-2020-0490","article-title":"Consensus statement by the American Association of Clinical Endocrinologists and American College of Endocrinology on the management of Dyslipidemia and Prevention of cardiovascular disease algorithm \u20132020 executive summary","volume":"26","author":"Handelsman","year":"2020","journal-title":"Endocr Pract"},{"issue":"1","key":"10.1016\/j.ahj.2025.06.010_bib0027","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2024.53300","article-title":"Lipoprotein a testing patterns in the veterans health administration","volume":"8","author":"Chen","year":"2025","journal-title":"JAMA Netw Open"},{"issue":"2","key":"10.1016\/j.ahj.2025.06.010_bib0028","doi-asserted-by":"crossref","DOI":"10.1136\/openhrt-2022-002060","article-title":"Lipoprotein(a) levels in a global population with established atherosclerotic cardiovascular disease","volume":"9","author":"Nissen","year":"2022","journal-title":"Open Heart"},{"issue":"14","key":"10.1016\/j.ahj.2025.06.010_bib0029","doi-asserted-by":"crossref","first-page":"e331","DOI":"10.1093\/eurjpc\/zwac124","article-title":"Lipoprotein(a) testing in clinical practice: real-life data from a large healthcare provider","volume":"29","author":"Zafrir","year":"2022","journal-title":"Eur J Prev Cardiol"},{"key":"10.1016\/j.ahj.2025.06.010_bib0030","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1016\/j.atherosclerosis.2023.01.014","article-title":"Trends and consequences of lipoprotein(a) testing: cross-sectional and longitudinal health insurance claims database analyses","volume":"367","author":"St\u00fcrzebecher","year":"2023","journal-title":"Atherosclerosis"},{"issue":"10","key":"10.1016\/j.ahj.2025.06.010_bib0031","doi-asserted-by":"crossref","DOI":"10.1093\/eurjpc\/zwae155","article-title":"Trends and disparities in lipoprotein(a) testing in a large integrated US health system, 2000\u201323","volume":"31","author":"Faaborg-Andersen","year":"2024","journal-title":"Eur J Prev Cardiol"},{"key":"10.1016\/j.ahj.2025.06.010_bib0032","doi-asserted-by":"crossref","first-page":"144","DOI":"10.1016\/j.atherosclerosis.2022.01.022","article-title":"Trends in testing and prevalence of elevated lp(a) among patients with aortic valve stenosis","volume":"349","author":"Bhatia","year":"2022","journal-title":"Atherosclerosis"}],"container-title":["American Heart Journal"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0002870325001991?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0002870325001991?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,1,7]],"date-time":"2026-01-07T04:57:01Z","timestamp":1767761821000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0002870325001991"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,11]]},"references-count":32,"alternative-id":["S0002870325001991"],"URL":"https:\/\/doi.org\/10.1016\/j.ahj.2025.06.010","relation":{},"ISSN":["0002-8703"],"issn-type":[{"value":"0002-8703","type":"print"}],"subject":[],"published":{"date-parts":[[2025,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Global lipoprotein (a) testing trends from 2015 to 2023","name":"articletitle","label":"Article Title"},{"value":"American Heart Journal","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ahj.2025.06.010","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 Elsevier Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}]}}